Pluripotent stem cell-derived natural killer cells for cancer therapy

被引：60

作者：

Knorr, David A.

Kaufman, Dan S. ^{[1
]}

机构：

[1] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA

来源：

TRANSLATIONAL RESEARCH | 2010年 / 156卷 / 03期

关键词：

HIGH-DOSE INTERLEUKIN-2; T-CELLS; NK CELLS; GENETIC-MODIFICATION; IN-VIVO; LIGAND INCOMPATIBILITY; ADVERSE EVENT; STROMAL CELLS; PHASE-I; DIFFERENTIATION;

D O I：

10.1016/j.trsl.2010.07.008

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

100118 [医学信息学]; 100208 [临床检验诊断学];

摘要：

Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) provide an accessible, genetically tractable, and homogenous starting cell population to efficiently study human blood cell development. These cell populations provide platforms to develop new cell-based therapies to treat both malignant and nonmalignant hematological diseases. Our group previously demonstrated the ability of hESC-derived hematopoietic precursors to produce functional natural killer (NK) cells as well as an explanation of the underlying mechanism responsible for the inefficient development of land B cells from hESCs. hESCs and iPSCs, which can be engineered reliably in vitro, provide an important new model system to study human lymphocyte development and produce enhanced cell-based therapies with the potential to serve as a "universal" source of antitumor lymphocytes. This review will focus on the application of hESC-derived NK cells with currently used and novel therapeutics for clinical trials, barriers to translation, and future applications through genetic engineering approaches. (Translational Research 2010;156:147-154)

引用

页码：147 / 154

页数：8

共 79 条

[1]

AKIRA N, 2009, J CELL PHYSL, V221, P367

[2]

Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias [J].